for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novavax, Inc.

NVAX.O

Latest Trade

139.60USD

Change

13.91(+11.07%)

Volume

15,658,183

Today's Range

118.50

 - 

147.50

52 Week Range

3.65

 - 

189.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
125.69
Open
119.26
Volume
15,658,183
3M AVG Volume
88.62
Today's High
147.50
Today's Low
118.50
52 Week High
189.40
52 Week Low
3.65
Shares Out (MIL)
63.66
Market Cap (MIL)
8,001.42
Forward P/E
-23.27
Dividend (Yield %)
--

Next Event

Novavax Inc Annual Shareholders Meeting

Latest Developments

More

Novavax Says Interim Data In Covid-19 Phase 3 Trial In Uk Expected As Soon As Early Q1 2021

Novavax Appoints Gregory Covino As CFO And Announces Leadership Updates

Novavax Reports Q3 Rev Of $157 Million Versus $2.5 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novavax, Inc.

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Industry

Biotechnology & Drugs

Contact Info

21 Firstfield Rd

GAITHERSBURG, MD

20878-1757

United States

+1.240.2682000

http://www.novavax.com/

Executive Leadership

James Francis Young

Independent Chairman of the Board

Stanley C. Erck

President, Chief Executive Officer, Director

Gregory F. Covino

Chief Financial Officer, Executive Vice President

Gregory M. Glenn

President, Research and Development

Jill Hoyt

Chief Human Resource Officer, Executive Vice President

Key Stats

2.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.6K
EPS (USD)

2017

-12.600

2018

-10.000

2019

-5.510

2020(E)

-5.402
Price To Earnings (TTM)
--
Price To Sales (TTM)
39.08
Price To Book (MRQ)
74.31
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
143.88
LT Debt To Equity (MRQ)
125.64
Return on Investment (TTM)
-64.27
Return on Equity (TTM)
-49.16

Latest News

Latest News

Novavax expects delayed U.S. COVID-19 vaccine trial to start in coming weeks

Novavax Inc on Monday pushed back the start of a U.S.-based, late-stage trial for its experimental COVID-19 vaccine for the second time and now expects it to begin in the coming weeks instead of November.

Novavax delays U.S. COVID-19 vaccine trial again, now sees start in the coming weeks

Vaccine maker Novavax Inc said on Monday it has pushed back the start of a U.S.-based, late-stage trial for its experimental COVID-19 vaccine and now expects it to begin in the coming weeks instead of November.

Factbox: EU tries to catch-up after U.S., UK spend billions to secure coronavirus vaccines

The European Union on Wednesday entered into a deal with Pfizer and BioNTech for the supply of up to 300 million doses of their COVID-19 vaccine candidate, as it tries to catch up with the United States and United Kingdom to secure supplies of experimental vaccines.

India's Serum says made 40 million doses of AstraZeneca's COVID vaccine, to make Novavax shot soon

Serum Institute of India, the world's largest vaccine producer, said on Thursday it has made 40 million doses of AstraZeneca's potential COVID-19 vaccine, and would soon begin making Novavax's rival shot, as they both seek regulatory approval.

India's Serum says produced 40 mln doses of AstraZeneca COVID-19 vaccine

Serum Institute of India, the world's largest vaccine producer, said on Thursday it has made 40 million doses of AstraZeneca's potential COVID-19 vaccine, and would soon begin making Novavax's rival shot, as they both seek regulatory approval.

Janssen, Novavax plan Mexican late stage COVID-19 vaccine trials, minister says

Johnson & Johnson's Janssen unit has received the green light to carry out late stage trials for its coronavirus vaccine in Mexico, Foreign Minister Marcelo Ebrard on Tuesday. He said U.S. vaccine developer Novavax Inc earlier this month also presented health authorities...

Novavax on track to begin U.S. trial of COVID-19 vaccine this month

Novavax Inc said on Monday it was on track to begin a delayed U.S.-based, late-stage study of its experimental coronavirus vaccine later this month.

UPDATE 1-Novavax ends Q3 with $334.2 mln cash ahead of U.S. trial of COVID-19 vaccine

Novavax Inc said on Monday it ended the third quarter with $334.2 million in cash and cash equivalents, as it prepares to start a delayed U.S.-based late-stage trial of its COVID-19 vaccine candidate later this month.

Novavax ends Q3 with $334.2 mln cash ahead of U.S. trial of COVID-19 vaccine

Novavax Inc said on Monday it ended the third quarter with $334.2 million in cash and cash equivalents, as the vaccine developer prepares to start a delayed U.S.-based late-stage trial of its COVID-19 vaccine candidate later this month.

Novavax's experimental coronavirus vaccine gets U.S. FDA's 'fast-track' status

Novavax Inc said on Monday its experimental coronavirus vaccine had gained the U.S. Food and Drug Administration's "fast-track" status.

Novavax to supply 40 million doses of COVID-19 vaccine to Australia

Novavax Inc said on Wednesday it has signed an agreement with the Australian government to supply 40 million doses of its COVID-19 vaccine candidate, NVX-CoV2373.

Novavax to supply 40 mln doses of COVID-19 vaccine to Australia

Novavax Inc said on Wednesday it has signed an agreement with the Australian Government to supply 40 million doses of the its COVID-19 vaccine candidate, NVX-CoV2373.

Novavax delays U.S. trial of COVID-19 vaccine to November

Novavax Inc <NVAX.O> on Tuesday delayed the start of a late-stage U.S. trial of its experimental coronavirus vaccine by roughly a month to the end of November, citing delays in scaling up the manufacturing process.

REFILE-UPDATE 1-Novavax delays U.S. trial start of COVID-19 vaccine to November

Novavax Inc on Tuesday delayed the timeline for beginning a late-stage U.S. trial of its experimental coronavirus vaccine by roughly one month.

Novavax expects data from UK trial of coronavirus vaccine in first-quarter 2021

Novavax Inc said on Tuesday it expects interim data from a late-stage UK trial of its coronavirus vaccine in the first quarter of next year.

Novavax to explore combined influenza/COVID-19 vaccine for use post pandemic

Novavax Inc said on Tuesday it has set up a team of company veterans as it seeks U.S. regulatory approval for its seasonal influenza vaccine and to help develop a combined influenza/COVID-19 vaccine for use after the pandemic.

Serum Institute to boost production of COVID-19 vaccine doses to 200 million

Serum Institute of India will make up to 200 million COVID-19 vaccine doses for poorer countries, including India, next year, as the Bill & Melinda Gates Foundation and GAVI vaccines alliance have doubled their funding, the company said on Tuesday.

FACTBOX-The race for a coronavirus vaccine

More than 150 potential vaccines are being developed and tested globally to stop the COVID-19 pandemic, with 38 in human trials, according to the World Health Organization (WHO). The following list tracks the latest developments from major drugmakers and research institutes...

Endo starts manufacturing Novavax's potential COVID-19 vaccine

Generic drugmaker Endo said on Friday it was manufacturing Novavax Inc's experimental COVID-19 vaccine, sending its shares up 10% before the trading bell.

Novavax signs manufacturing deal with Endo for potential COVID-19 vaccine

Novavax Inc has signed an agreement with Endo International for manufacturing its experimental COVID-19 vaccine, the generic drugmaker said on Friday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up